KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.90

The obesity paradox: Retinopathy, obesity, and circulating risk markers in youth with type 2 diabetes in the TODAY Study.

Lynne L Levitsky, Kimberly L Drews, Morey Haymond, Rose A Glubitosi-Klug, Lorraine E Levitt Katz, Mihai Mititelu, William Tamborlane, Jeanie B Tryggestad, Ruth S Weinstock, TODAY Study Group

J Diabetes Complications 36(11) 108259

PMID36150365
PMCIDPMC12396272
DOI10.1016/j.jdiacomp.2022.108259
发表日期2022-09-23
入排依据:The record describes a non-oncology clinical trial (TODAY Study) focused on type 2 diabetes and diabetic retinopathy in adolescents. Although it is a randomized, Phase III study in humans, the subject matter and outcomes are not relevant to oncology Kaplan-Meier digitization.
摘要

摘要

AIM: To understand the relationship of obesity and 27 circulating inflammatory biomarkers to the prevalence of non-proliferative diabetic retinopathy (NPDR) in youth with type 2 diabetes. METHODS: Youth with type 2 diabetes who participated in the TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) study were followed for 2-6.5 years. Digital fundus photographs were obtained in the last year of the study. Blood samples during the study were processed for inflammatory biomarkers, and these were correlated with obesity tertiles and presence of retinopathy. RESULTS: Higher BMI was associated with an increase in circulating levels of metabolic biomarkers including high sensitivity C-reactive protein (hsCRP), plasminogen activator inhibitor 1 (PAI-1), fibrinogen, LDL-cholesterol (LDL-C) and Apolipoprotein B (ApoB), tumor necrosis factor receptors 1 and 2 (TNFR-1 and -2), interleukin 6 (IL-6), E-selectin, and homocysteine, as well as a decrease in the metabolic risk markers HDL-cholesterol (HDLC), and insulin-like growth factor binding protein 1 (IGFBP-1). Although NPDR risk decreased with increasing obesity, it was not associated with any of the measured biomarkers. CONCLUSIONS: Circulating levels of measured biomarkers did not elucidate the "obesity paradox" of decreased NPDR in the most obese participants in the TODAY study. TRIAL REGISTRATION: clinicaltrials.govNCT00081328.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。